May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Intraocular Pressure After Intravitreal Injection of Triamcinolone Acetonide Following Vitrectomy for Macular Edema
Author Affiliations & Notes
  • T. Yamashita
    Department of Ophthalmology, Kagoshima University, Kagoshima–Shi, Japan
  • A. Uemura
    Department of Ophthalmology, Kagoshima City Hospital, Kagoshima–Shi, Japan
  • H. Kita
    Department of Ophthalmology, Kagoshima City Hospital, Kagoshima–Shi, Japan
  • T. Sakamoto
    Department of Ophthalmology, Kagoshima University, Kagoshima–Shi, Japan
  • Footnotes
    Commercial Relationships  T. Yamashita, None; A. Uemura, None; H. Kita, None; T. Sakamoto, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Yamashita, A. Uemura, H. Kita, T. Sakamoto; Intraocular Pressure After Intravitreal Injection of Triamcinolone Acetonide Following Vitrectomy for Macular Edema . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the long–term intraocular pressure (IOP) response after intravitreal injections of different doses of intravitreal triamcinolone acetonide (TA) at the end of pars plana vitrectomy (PPV) for macular edema secondary to diabetic retinopathy or retinal vein occlusion.

Methods: : Twenty–seven eyes of 25 consecutive patients with macular edema associated with diabetic retinopathy (n=18) or retinal vein occlusion (n=9) who underwent PPV between January 2003 and December 2003 were enrolled. At the end of vitrectomy for those eyes, different doses of TA were randomly injected into the vitreous cavity: 14 eyes with 5mg TA (low TA group) and 13 eyes with 10mg TA (high TA group). The main outcome measure was intraocular pressure (IOP).

Results: : All patients were followed up at least 12 months. Preoperative IOP was 12.6±2.6 mmHg (mean±standard deviation [SD]) in low TA group and 13.2±2.1 mmHg in high TA group. Postoperatively, IOP increased to a mean maximum of 20.6±5.5 mmHg in low TA group and 31.5±3.5 mmHg in high TA group (p<.01 for both groups). The difference between groups was also significant (p<.05). Five of 14 eyes (36%) in low TA group and 10 of 13 eyes (77%) in high TA group had an elevation of IOP exceeding 21 mmHg (p=0.03). The median interval from surgery to reach a maximal IOP was 7 days in both groups. The significant IOP elevation lasted 3 months in low TA group and 6 months in high TA group.

Conclusions: : After injection of TA into the vitreous cavity at the end of PPV for macular edema, dose–dependent IOP elevation was observed, starting from early postoperative days and returning to normal values after several months. Additionally, the proportion of eyes with elevated IOP and the time course of IOP changes were different from eyes with intravitreal TA injection in the absence of vitrectomy.

Keywords: drug toxicity/drug effects • intraocular pressure • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×